It’s official: Roche is a Car-T player

When in the middle of the last decade Car-T took off there was a major elephant in the room: Roche, the world’s biggest oncology player, was refusing to buy in. After the Swiss group handed $110m to Poseida today investors no longer need to fret about this problem.